Drugs / TASO-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04862767 | Mar 2021 → Aug 2023 | cancer | Autotelicbio | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-11-16 | Mateon Therapeutics | Results Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers oncotelic.com ↗
In the safety cohort treated during the Trial, the standard dosage of 140mg/m2 of OT-101was well tolerated in combination with IL-2, which has allowed for ongoing dose escalation to 190 mg/m2. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-11-16 | Mateon Therapeutics | Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers oncotelic.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TASO-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04862767 ↗ |
| Modality | Antisense oligonucleotide | “TGF-β2 targeting anti-sense oligonucleotide” NCT04862767 ↗ |
| Route | Other | “96 hour continuous infusion” NCT04862767 ↗ |
| Target | TGFB2 | “TGF-β2 targeting anti-sense oligonucleotide” NCT04862767 ↗ |